radium Ra 223 dichloride (Xofigo, BAY88-8223)

DRUG2 trials

Sponsors

Bayer

Conditions

Bone DiseasesNeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

CompletedNCT02442063

BayerBone Diseases, Neoplasms

Start: 2015-08-31End: 2016-10-31Updated: 2016-11-30

Unknown Phase

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

WithdrawnNCT03325127

BayerProstatic Neoplasms, Castration-Resistant

Start: 2017-10-30End: 2018-09-28Updated: 2018-10-31

Related Papers

Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup

Cancer Research2018-02-15